The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management.
IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI’s total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners.
IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio.
In total, IHI will contribute up to EUR 135 million to projects funded under IHI call 1. When preparing their budgets, applicants will have to ensure that at least 45 % of the total project costs are met via contributions from IHI private partners and/or IHI contributing partners.
For IHI call 2, the IHI contribution is around EUR 22 million, a figure that is matched by the contributions committed by private and contributing partners.
IHI call 1 (single stage call)
Deadline: 20/09/2022 at 17:00 Brussels time.
IHI call 2 (two stage call)
First stage deadline: 20/09/2022 at 17:00 Brussels time.
Second stage deadline: 28/02/2023 at 17:00 Brussels time.
For more information, please contact email@example.com